Liver Cancer

Published by: Karger  

People

  1. Abou-Alfa
    Abou-Alfa
  2. Crane
    Crane
  3. Do
    Do
  4. Erinjeri
    Erinjeri
  5. Harding
    Harding
  6. O'Reilly
    O'Reilly
  7. Solit
    Solit

Groups

  1. Department of Medicine (7)
  2. Gastrointestinal Oncology Service (7)
  3. Solid Tumor Oncology Division (7)
  4. Center for Pancreatic Cancer Research (2)
  5. Radiology, Department of (2)
  6. Advanced Practice Providers (1)
  7. Body Imaging Service (1)
  8. GSK Faculty (1)
  9. Genitourinary Oncology Service (1)
  10. Human Oncology and Pathogenesis Program (1)
Search Within
Formats
  1. Journal Article (7)
  2. Review (1)
Groups
  1. Department of Medicine (7)
  2. Gastrointestinal Oncology Service (7)
  3. Solid Tumor Oncology Division (7)
  4. Center for Pancreatic Cancer Research (2)
  5. Radiology, Department of (2)
  6. Advanced Practice Providers (1)

More Groups

People
  1. Ghassan Abou-Alfa (7)
  2. James Harding (2)
  3. Alison O'Neill (1)
  4. Amin Yaqubie (1)
  5. Christopher Crane (1)
  6. David Solit (1)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (2)
  4. 2022 (2)
  5. 2021 (1)
  6. 2017 (1)
Publishers
  1. Karger (8)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma
    Journal Article

    Abou-Alfa, G. K.; Meyer, T.; Do, R. K. G.; Piha-Paul, S. A.; Light, J. S.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Harding, J. J.; Al-Rajabi, R.; more...
    Liver Cancer (2025)

    Fulltext@MSK | Save
  • PHOCUS: A phase 3, randomized, open-label study of sequential treatment with pexa-vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma
    Journal Article

    Abou-Alfa, G. K.; Galle, P. R.; Chao, Y.; Erinjeri, J.; Heo, J.; Borad, M. J.; Luca, A.; Burke, J.; Pelusio, A.; Agathon, D.; more...
    Liver Cancer (2024)

    Fulltext@MSK | Save
  • Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases
    Journal Article

    De, B.; Upadhyay, R.; Liao, K.; Kumala, T.; Shi, C.; Dodoo, G.; Abi Jaoude, J.; Corrigan, K. L.; Manzar, G. S.; Marqueen, K. E.; more...
    Liver Cancer (2023)

    Fulltext@MSK | Save
  • Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): A multicenter, non-randomized, open-label, phase 2 trial
    Journal Article

    Ren, Z.; Ducreux, M.; Abou-Alfa, G. K.; Merle, P.; Fang, W.; Edeline, J.; Li, Z.; Wu, L.; Assenat, E.; Hu, S.; more...
    Liver Cancer (2023)

    Fulltext@MSK | Save
  • First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/Ezurpimtrostat in patients with primary and secondary liver cancers
    Journal Article

    Harding, J. J.; Awada, A.; Roth, G.; Decaens, T.; Merle, P.; Kotecki, N.; Dreyer, C.; Ansaldi, C.; Rachid, M.; Mezouar, S.; more...
    Liver Cancer (2022)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Journal Article

    Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; Chan, Y. W.; more...
    Liver Cancer (2022)

    Fulltext@MSK | Save
  • Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: A network meta-analysis
    Review

    Vogel, A.; Rimassa, L.; Sun, H. C.; Abou-Alfa, G. K.; El-Khoueiry, A.; Pinato, D. J.; Sanchez Alvarez, J.; Daigl, M.; Orfanos, P.; Leibfried, M.; more...
    Liver Cancer (2021)

    Fulltext@MSK | Save
  • Hepatocellular carcinoma: Therapeutic guidelines and medical treatment
    Journal Article

    Kudo, M.; Trevisani, F.; Abou-Alfa, G. K.; Rimassa, L.
    Liver Cancer (2017)

    Fulltext@MSK | Save

    • Liver Cancer – authorized name for:

    Name ISSN / ISBN Publisher
    Liver Cancer 22351795 S. Karger AG
    Liver Cancer 2235-1795 Karger
    Liver Cancer 2235-1795 Karger
    Liver Cancer 2235-1795 Karger
    Liver Cancer 22351795 Authors
    Liver Cancer 22351795 The Author(s)
    Liver Cancer 22351795 S. Karger AG